Global PROteolysis Targeting Chimera (PROTAC) Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global PROteolysis Targeting Chimera (PROTAC) Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
A proteolysis targeting chimera (PROTAC) is a heterobifunctional small molecule composed of two active domains and a linker capable of removing specific unwanted proteins. Rather than acting as a conventional enzyme inhibitor, a PROTAC works by inducing selective intracellular proteolysis. PROTACs consist of two covalently linked protein-binding moleculesone capable of engaging an E3 ubiquitin ligase, and another that binds to a target protein meant for degradation. Recruitment of the E3 ligase to the target protein results in ubiquitination and subsequent degradation of the target protein by the proteasome. Because PROTACs need only to bind their targets with high selectivity (rather than inhibit the target protein's enzymatic activity), there are currently many efforts to retool previously ineffective inhibitor molecules as PROTACs for next-generation drugs.
PROteolysis Targeting Chimera (PROTAC) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global PROteolysis Targeting Chimera (PROTAC) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Oncology and Others are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for PROteolysis Targeting Chimera (PROTAC) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, PROteolysis Targeting Chimera (PROTAC) key manufacturers include Arvinas, Kymera, C4 therapeutics, Captor therapeutics, Vividion, Cullgen, Pfizer, Merck and Genentech, etc. Arvinas, Kymera, C4 therapeutics are top 3 players and held % sales share in total in 2022.
PROteolysis Targeting Chimera (PROTAC) can be divided into ARV-110, ARV-471, KYM-001 and Others, etc. ARV-110 is the mainstream product in the market, accounting for % sales share globally in 2022.
PROteolysis Targeting Chimera (PROTAC) is widely used in various fields, such as Oncology and Others, etc. Oncology provides greatest supports to the PROteolysis Targeting Chimera (PROTAC) industry development. In 2022, global % sales of PROteolysis Targeting Chimera (PROTAC) went into Oncology filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global PROteolysis Targeting Chimera (PROTAC) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Arvinas
Kymera
C4 therapeutics
Captor therapeutics
Vividion
Cullgen
Pfizer
Merck
Genentech
AstraZeneca
Amgen
Bayer
Segment by Type
ARV-110
ARV-471
KYM-001
Others
Oncology
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the PROteolysis Targeting Chimera (PROTAC) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of PROteolysis Targeting Chimera (PROTAC), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the PROteolysis Targeting Chimera (PROTAC) industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of PROteolysis Targeting Chimera (PROTAC) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, PROteolysis Targeting Chimera (PROTAC) introduction, etc. PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of PROteolysis Targeting Chimera (PROTAC) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
PROteolysis Targeting Chimera (PROTAC) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global PROteolysis Targeting Chimera (PROTAC) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Oncology and Others are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for PROteolysis Targeting Chimera (PROTAC) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, PROteolysis Targeting Chimera (PROTAC) key manufacturers include Arvinas, Kymera, C4 therapeutics, Captor therapeutics, Vividion, Cullgen, Pfizer, Merck and Genentech, etc. Arvinas, Kymera, C4 therapeutics are top 3 players and held % sales share in total in 2022.
PROteolysis Targeting Chimera (PROTAC) can be divided into ARV-110, ARV-471, KYM-001 and Others, etc. ARV-110 is the mainstream product in the market, accounting for % sales share globally in 2022.
PROteolysis Targeting Chimera (PROTAC) is widely used in various fields, such as Oncology and Others, etc. Oncology provides greatest supports to the PROteolysis Targeting Chimera (PROTAC) industry development. In 2022, global % sales of PROteolysis Targeting Chimera (PROTAC) went into Oncology filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global PROteolysis Targeting Chimera (PROTAC) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Arvinas
Kymera
C4 therapeutics
Captor therapeutics
Vividion
Cullgen
Pfizer
Merck
Genentech
AstraZeneca
Amgen
Bayer
Segment by Type
ARV-110
ARV-471
KYM-001
Others
Segment by Application
Oncology
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the PROteolysis Targeting Chimera (PROTAC) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of PROteolysis Targeting Chimera (PROTAC), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the PROteolysis Targeting Chimera (PROTAC) industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of PROteolysis Targeting Chimera (PROTAC) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, PROteolysis Targeting Chimera (PROTAC) introduction, etc. PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of PROteolysis Targeting Chimera (PROTAC) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices